Transplantation & Cellular Therapy
Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 14, 2023
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
View More
Cecilia BrownChronic Lymphocytic Leukemia | August 30, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Cecilia BrownTransplantation & Cellular Therapy | August 29, 2023
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Cecilia BrownMantle Cell Lymphoma | August 23, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Leah SherwoodAcute Myeloid Leukemia | July 28, 2023
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Cecilia BrownPrint | July 11, 2023
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Cecilia BrownTransplantation & Cellular Therapy | April 17, 2023
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Cecilia BrownTransplantation & Cellular Therapy | April 11, 2023
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Cecilia BrownTransplantation & Cellular Therapy | April 10, 2023
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
Cecilia BrownTransplantation & Cellular Therapy | March 3, 2023
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
Cecilia BrownTransplantation & Cellular Therapy | March 2, 2023
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Cecilia BrownViewpoints | February 28, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 23, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Leah SherwoodTransplantation & Cellular Therapy | February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Cecilia BrownTransplantation & Cellular Therapy | February 10, 2023
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Editorial Board